Literature DB >> 2874280

Unexpected mobilisation of lead during cisplatin chemotherapy.

A M el-Sharkawi, W D Morgan, S Cobbold, M B Jaib, C J Evans, L J Somervaille, D R Chettle, M C Scott.   

Abstract

During an investigation by X-ray fluorescence of platinum uptake in the kidney after chemotherapy with cisplatin, lead was found to have accumulated in the kidney in four subjects. The average kidney lead burden in one case exceeded 800 micrograms/g. Although two of the subjects had been occupationally exposed to lead, the other two had not. The tibia lead burden was also high in the two subjects in whom it was measured. The origins of this mobilised lead and the implications for cisplatin nephrotoxicity are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874280     DOI: 10.1016/s0140-6736(86)92072-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Lead poisoning in an adult: lead mobilization by pregnancy?

Authors:  Matthias L Riess; Josiah K Halm
Journal:  J Gen Intern Med       Date:  2007-06-12       Impact factor: 5.128

2.  In vivo tibia lead measurements as an index of cumulative exposure in occupationally exposed subjects.

Authors:  L J Somervaille; D R Chettle; M C Scott; D R Tennant; M J McKiernan; A Skilbeck; W N Trethowan
Journal:  Br J Ind Med       Date:  1988-03

3.  Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding.

Authors:  J H Yuk; C H Nightingale; K R Sweeney; R Quintiliani; J T Lettieri; R W Frost
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  Changes in serum iron levels following very high-dose cisplatin.

Authors:  C F Pollera; F Ameglio; S Reina; M Nardi; M R Abbolito; C Parracino
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 5.  Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms.

Authors:  H Hu; M Rabinowitz; D Smith
Journal:  Environ Health Perspect       Date:  1998-01       Impact factor: 9.031

6.  Cisplatin-associated anemia: an erythropoietin deficiency syndrome.

Authors:  P A Wood; W J Hrushesky
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Inhibition of norfloxacin absorption by antacids.

Authors:  D E Nix; J H Wilton; B Ronald; L Distlerath; V C Williams; A Norman
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

8.  Case report 669: Osteonecrosis of bone associated with intraarterial therapy using cisplatin.

Authors:  P Wuisman; R Erlemann; A Roessner; A Bosse; C Kusniez-Glaz
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

9.  The use of K X-ray fluorescence for measuring lead burden in epidemiological studies: high and low lead burdens and measurement uncertainty.

Authors:  H Hu; F L Milder; D E Burger
Journal:  Environ Health Perspect       Date:  1991-08       Impact factor: 9.031

Review 10.  An age-specific kinetic model of lead metabolism in humans.

Authors:  R W Leggett
Journal:  Environ Health Perspect       Date:  1993-12       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.